You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKesson
Moodys
Johnson and Johnson
Express Scripts

Last Updated: November 23, 2020

DrugPatentWatch Database Preview

TEFLARO Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Teflaro patents expire, and what generic alternatives are available?

Teflaro is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-nine patent family members in thirty-four countries.

The generic ingredient in TEFLARO is ceftaroline fosamil. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ceftaroline fosamil profile page.

US ANDA Litigation and Generic Entry Outlook for Teflaro

Teflaro was eligible for patent challenges on October 29, 2014.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 10, 2031. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for TEFLARO
Drug Prices for TEFLARO

See drug prices for TEFLARO

Generic Entry Opportunity Date for TEFLARO
Generic Entry Date for TEFLARO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TEFLARO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Olayemi Osiyemi MDPhase 4
Basim AsmarPhase 1
Sharp HealthCarePhase 4

See all TEFLARO clinical trials

Pharmacology for TEFLARO
Paragraph IV (Patent) Challenges for TEFLARO
Tradename Dosage Ingredient NDA Submissiondate
TEFLARO POWDER;INTRAVENOUS ceftaroline fosamil 200327 2014-10-29

US Patents and Regulatory Information for TEFLARO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-001 Oct 29, 2010 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Allergan TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-002 Oct 29, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan TEFLARO ceftaroline fosamil POWDER;INTRAVENOUS 200327-001 Oct 29, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for TEFLARO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1043327 422 Finland   Start Trial
1043327 SPC/GB13/004 United Kingdom   Start Trial PRODUCT NAME: CEFTAROLINE FOSAMIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/12/785/001 20120823
1043327 92134 Luxembourg   Start Trial PRODUCT NAME: CEFTAROLINE FOSAMIL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ZINFORO)
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Express Scripts
Colorcon
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.